Klotho Neurosciences, Inc. (KLTO)
NASDAQ: KLTO · Real-Time Price · USD
0.501
+0.011 (2.24%)
At close: Dec 5, 2025, 4:00 PM EST
0.505
+0.004 (0.80%)
After-hours: Dec 5, 2025, 7:52 PM EST
Company Description
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Klotho Neurosciences, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Joseph Sinkule |
Contact Details
Address: 13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States | |
| Phone | 833 931 6330 |
| Website | klothoneuro.com |
Stock Details
| Ticker Symbol | KLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907223 |
| ISIN Number | US49876K1034 |
| Employer ID | 86-2727441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Sinkule Pharm.D. | Founder, Chief Executive Officer, Chairman of the Board and Secretary |
| Jeffrey LeBlanc | Chief Financial Officer |
| Dr. Shalom Z. Hirschman M.D. | Medical Advisor and Director |
| Peter J. Moriarty | Chief Business Officer |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Officer and Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 30, 2025 | 424B3 | Prospectus |
| Sep 25, 2025 | 8-K | Current Report |
| Sep 25, 2025 | 8-K | Current Report |
| Aug 18, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 12, 2025 | 8-K | Current Report |
| Jul 28, 2025 | 424B5 | Filing |